Лечение нефрогенной анемии: вчера, сегодня, завтра


В.Ю. Шило, А.Ю. Денисов

Кафедра нефрологии ФПДО МГМСУ, Москва; ЦКБ УД Президента РФ, Москва
Обсуждаются подходы к оптимизации применения препаратов железа при нефрогенной анемии.

Литература


1. Российские национальные рекомендации по диагностике и лечению анемии при хронической болезни почек. Анемия 2006; № 3: 3–19.
2. Шило В.Ю. Активатор рецепторов эритропоэтина длительного действия – новый подход к оптимизации лечения нефрогенной анемии. Клин. фармакология и терапия. 2009. № 5. С. 58–62.
3. Шило В.Ю. Новый эритропоэз-стимулирующий препарат Аранесп (дарбэпоэтин альфа) в коррекции анемии почечного генеза. Нефрология и диализ. 2007. Т. 9. № 3. С. 1–9.
4. Шило В.Ю., Хасабов Н.Н. Анемия при хронической болезни почек. Лечащий врач. 2008. № 1. С. 25–31.
5. Шило В.Ю. Биоаналоги в лечении анемии при хронической болезни почек: потенциальная польза или неоправданный риск? Лечащий врач. 2007. № 9–10. С. 56–64.
6. Шнайдер A. Сопоставление распределения изоформ фармацевтических препаратов эритропоэтина с использованием двумерного гельэлектрофореза. Клиническая нефрология. 2010. № 2. С. 50–53.
7. Besarab A., Bolton W.K., Browne J.K. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584–590.
8. Canaud B., Mingardi G., Braun J. et al. Оn behalf of the STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial. Transplant. 2008, Aug 26. [Epub ahead of print] PMID: 18586762.
9. Carrera F., Lok C.E., de Francisco A. et al. PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010; 25(12):4009–4017.
10. Castelao et al. Oral presentation Su057. Congress ERA-EDTA, Munich, 2010
11. Collins A.J., Brenner R.M., Ofman J.J. et al. Epoetin alfa use in pa-tients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am. J. Kidney. Dis. 2005; 46 (3): 481–488.
12. De Francisco A.L., Sulowicz W., Klinger M. et al. BA16260 Study Invesigators. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int. J. Clin. Pract. 2006; 60(12):1687–1696. Erratum in: Int. J. Clin. Pract. 2007;61(10):1776–1777.
13. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355(20): 2071–2084.
14. Eckardt K.U., Macdougall I.C., Froissart M., et al. Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with Hematide TM. Nephrol Dial Transplant 2008;1(Suppl. 2):i216. (abstract)
15. Eschbach J.W., Egrie J.C., Downing M.R. et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1990;4; 323 (14):999–1000.
16. Fliser D., Kleophas W., Dellanna F. et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin. 2010;26(5):1083–1089.
17. Gilbertson D.T., Ebben J.P., Foley R.N. et al. Hemoglobin level variability: associations with mortality. Clin. J. Am. Soc. Nephrol 2008;3(1):133–138.
18. Hampl H., Hennig L., Rosenberger C. et al. Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients. Am J Nephrol 2005;25(3):211–220.
19. Jacobs K., Shoemaker C., Rudersdorf R. et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;6;313 (6005):806–810.
20. Jarsch M., Brandt M., Lanzendörfer M. et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008;81:63–69.
21. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am. J. Kidney Dis. 2007;50(3):471–530.
22. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am. J. Kidney Dis. 2006;47(5 Suppl. 3):S16–18.
23. Klinger M., Arias M., Vargemezis V. et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks com-pared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial (AMICUS). Am. J. Kidney Dis. 2007;50(6):989–1000.
24. Kupcova V., Sperl J., Pannier A. et al. The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A. Curr. Med. Res. Opin. 2008; 24 (7): 1943–1950.
25. Lacson E. Jr., Ofsthun N., Lazarus J.M. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am. J. Kidney Dis. 2003; 41 (1): 111–124.
26. Levin N.W., Fishbane S., Valdés Cañedo F. et al. Intravenous me-thoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007; 370:1415–1421.
27. Locatelli F., Aljama P., Bárány P., et al., European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1–47.
28. Locatelli F., Aljama P., Canaud B. et al.; Anaemia Working Group of European Renal Best Practice (ERBP).Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25(9):2846–50. Epub 2010 Jun 29.
29. Macdougall I.C., Robson R., Opatrna S. et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2006; 1: 1211–1215.
30. Macdougall I.C., Walker R., Provenzano R. et al. ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin. J. Am. Soc. Nephrol. 2008;3(2):337–347. Miyake T., Kung C.K., Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 1977;10;252 (15):5558–5564.
31. Oral A. The complete correction of post-transplant anemia reduces the rate of progression of chronic allograft nephropathy. Am J Transplantation. 2010;10:141.
32. Panchapakesan U., Sumual S., Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator). Int. J. Nanomedicine. 2007;2 (1):33–38.
33. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–2032.
34. Provenzano R., Besarab A., Macdougall I.C. et al. BA 16528 Study Investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study // Clin. Nephrol. 2007;67(5):306–317.
35. Regidor D.L., Kopple J.D., Kovesdy C.P. et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 2006;17:1181–1191.
36. Singh A.K., Fishbane S. The optimal hemoglobin in dialysis patients- a critical review. Semin Dial. 2008;21 (1):1–6. Review.
37. Singh A.K., Szczech L., Tang K.L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 2006;335:2085–2098.
38. Singh A.K., Milford E., Fishbane S. et al. Managing anemia in di-alysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008; 74(5):679–683.
39. Sulowicz W., Locatelli F., Ryckelynck J-P. et al. Оn behalf of the PROTOS study investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin. J. Am. Soc.
Nephrol. 2007;2:637–646.


Об авторах / Для корреспонденции


Шило В.Ю. – медицинский директор Б. Браун Руссланд Авитум Клиникс, доцент кафедры нефрологии ФПДО МГМСУ, к.м.н.;
Денисов А.Ю. – заведующий отделением гемодиализа ЦКБ УД Президента РФ, к.м.н.
E-mail: nephrolog@gmail.com


Похожие статьи


Бионика Медиа